Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies
Nano Letters · 05.11.2025 · 25 (44) · 15795-15808
DOI: 10.1021/acs.nanolett.5c03826 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nano Letters, online erschienen am 22.10.2025. Verfasst von Alexey V Yaremenko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Department, Oncology Unit, George Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54124, Gree…. Hauptthemen laut MEDLINE: Drug Delivery Systems, Lung Neoplasms, RNA, Messenger. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer tops the list of the deadliest malignancies, consistently resisting conventional therapies and fueling the urgent pursuit of novel treatment strategies. Messenger RNA (mRNA) nanomedicines are rapidly expanding from pandemic vaccinology to oncology, but achieving efficient and targeted delivery to the lung continues to be a significant obstacle. This Mini-Review highlights advances that enable lung-focused mRNA therapeutics. We show extracellular and intracellular barriers, including mucus, surfactant, alveolar macrophages, and endosomal sequestration. We outline how ionizable lipids, polymer-lipid hybrids, extracellular-vesicle mimetics, and selective organ-targeting chemistry overcome these barriers. We overview the therapeutic payload spectrum, from multiepitope vaccines and antibody factories to tumor-suppressor restoration and in vivo gene editing, highlighting first-in-human data in lung cancer. We discuss persistent bottlenecks: off-target editing, cytokine toxicity, and manufacturing speed and propose design rules to accelerate translation. By integrating sequence-level mRNA design with precision nanocarriers, mRNA technology can benefit lung cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Department, Oncology Unit, George Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
- Section of Biomedical Engineering, School of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
ORCID-Profile: Alexey V Yaremenko, Chuang Liu
Zitieren
APA
Yaremenko, A. V., Pechnikova, N. A., & Liu, C. (2025). Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies. Nano Letters, 25(44), 15795-15808. https://doi.org/10.1021/acs.nanolett.5c03826
Vancouver
Yaremenko AV, Pechnikova NA, Liu C. Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies. Nano Letters. 2025;25(44):15795-15808. doi:10.1021/acs.nanolett.5c03826
BibTeX
@article{Yaremenko2025,
author = {Yaremenko, Alexey V and Pechnikova, Nadezhda A and Liu, Chuang},
title = {Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies},
journal = {Nano Letters},
year = {2025},
volume = {25},
number = {44},
pages = {15795--15808},
doi = {10.1021/acs.nanolett.5c03826}
}
EUVIMED